Elucidation of the pathogenesis of inflammatory bowel disease based on selective IL-17F regulation via Dectin-1.

• Project/Area Number: 26460966
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Shiga University of Medical Science
• Principal Investigator: Ban Hiromitsu 滋賀医科大学, 医学部, 特任助教 (30598363)
• Co-Investigator(Kenkyū-buntansha): 馬場 重樹 滋賀医科大学, 医学部, 助教 (40422901)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000); Fiscal Year 2016: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000); Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000); Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
• Keywords: 炎症性腸疾患 / サイトカイン / アンチセンスオリゴ / Interleukin-17 / DSS腸炎マウス / インターロイキン / 炎症性サイトカイン / 腸炎モデルマウス / 抗炎症作用

Outline of Final Research Achievements

IL-17β is highly expressed from Dectin-1 positive cells with IL-1β. In addition, we have studied the introduction of antisense DNA nucleotide sequences into cells using β-1,3-D-gulcan, Schizophyllan as a carrier, in a Dectin-1 dependent manner. Based on these two studies, IL-17F highly expressed from Dectin-1 positive cells in intestinal inflammation model mice was suppressed by intracellular introduction of antisense DNA by using SPG-mediated Drug delivery system We will elucidate the role of IL-17F expressed from Dectin-1 positive cells and aim to develop new therapeutic agents for inflammatory bowel disease.

Research Products

• [Journal Article] Letter: CYP3A4/5 genotype status and outcome of vonoprazan-containing Helicobacter pylori eradication therapy in Japan. (2017)
  • Author(s): Sugimoto M, Ban H, Hira D, Kamiya T, Otsuka T, Inatomi O, Bamba S, Terada T, Andoh A.
  • Journal Title: Aliment Pharmacol Ther. Volume: 45 Issue: 7 Pages: 1009-1010
  • DOI: 10.1111/apt.13959
  • Peer Reviewed / Open Access
• [Journal Article] Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan. (2017)
  • Author(s): Sugimoto M, Sahara S, Ichikawa H, Kagami T, Ban H, Otsuka T, Andoh A, Furuta T.
  • Journal Title: Helicobacter. Volume: 22 Issue: 1 Pages: 1-8
  • DOI: 10.1111/hel.12319
  • Peer Reviewed
• [Journal Article] Efficacy of the Kyoto Classification of Gastritis in Identifying Patients at High Risk for Gastric Cancer (2017)
  • Author(s): 114.Sugimoto M, Ban H, Ichikawa H, Sahara S, Otsuka T, Inatomi O, Bamba S, Furuta T, Andoh A.
  • Journal Title: Internal Medicine Volume: 56 Issue: 6 Pages: 579-586
  • DOI: 10.2169/internalmedicine.56.7775
  • NAID: 130005450498
  • ISSN: 0918-2918, 1349-7235
  • Peer Reviewed
• [Journal Article] Influence of potassium-competitive acid blocker on the gut microbiome of Helicobacter pylori-negative healthy individuals. (2016)
  • Author(s): Otsuka T, Sugimoto M, Inoue R, Ohno M, Ban H, Nishida A, Inatomi O, Takahashi S, Naito Y, Andoh A.
  • Journal Title: Gut. Volume: 1 Issue: 9 Pages: 1-1
  • DOI: 10.1136/gutjnl-2016-313312
  • Peer Reviewed
• [Journal Article] Prognostic factors affecting early colectomy in patients with moderate to severe ulcerative colitis treated with calcineurin inhibitors. (2016)
  • Author(s): Ban H, Bamba S, Nishida A, Inatomi O, Shioya M, Takahashi KI, Imaeda H, Murata M, Sasaki M, Tsujikawa T, Andoh A.
  • Journal Title: Exp Ther Med. Volume: 12 Pages: 829-834
  • Peer Reviewed / Acknowledgement Compliant